GlassScriptPhysician profile
Mohan Madhusudanan
NPI 1548308463
$3,427.85
in general payments reported to CMS, 2019-2025
27 companies · $694 in 2025
The $694 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $989 · 2020: $246 · 2021: $223 · 2022: $384 · 2023: $507 · 2024: $384 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,585.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $611.31 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $530.78 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $463.41 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $381.21 | 2019-2022 | |
| Amgen INC. | $298.19 | 2019-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.77 | 2019-2025 | Jardiance |
| Boston Scientific Corporation | $110.38 | 2023-2025 | Watchman Flx, Watchman Access System |
| Gilead Sciences, INC. | $84.22 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $76.93 | 2019-2025 | Farxiga |
| Cvrx, INC. | $74.03 | 2025 | Barostim Neo System |
| Edwards Lifesciences Corporation | $57.80 | 2024-2025 | Sapien 3 Ultra Resilia |
| Sanofi-Aventis U.S. LLC | $55.86 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $53.85 | 2023-2024 | Verquvo |
| Regeneron Healthcare Solutions, INC. | $52.97 | 2019 | |
| Amarin Pharma, INC. | $48.53 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $42.50 | 2019 | |
| Biotronik INC. | $36.13 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.57 | 2021 | |
| Janssen Scientific Affairs, LLC | $30.27 | 2023-2024 | Xarelto |
| Bridgebio Pharma, INC. | $27.08 | 2025 | Attruby |
| Alnylam Pharmaceuticals INC. | $25.96 | 2025 | Onpattro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.08 | 2022-2024 | Lifevest |
| Lantheus Medical Imaging, INC. | $22.56 | 2020 | |
| Impulse Dynamics (USA) INC. | $19.90 | 2023 | Optimizer |
| Heartflow, INC. | $19.59 | 2025 | |
| Scpharmaceuticals INC. | $17.45 | 2024 | |
| Philips North America LLC | $12.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohan Madhusudanan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.